ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 173 filers reported holding ASCENDIS PHARMA A/S in Q2 2021. The put-call ratio across all filers is 4.45 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $1,205,857 | +66.3% | 13,511 | +99.8% | 0.06% | +107.1% |
| Q1 2023 | $725,022 | +27.2% | 6,762 | +44.9% | 0.03% | +33.3% |
| Q4 2022 | $569,981 | +127.1% | 4,667 | +91.7% | 0.02% | +133.3% |
| Q3 2022 | $251,000 | +20.7% | 2,435 | +8.7% | 0.01% | +50.0% |
| Q2 2022 | $208,000 | -88.3% | 2,241 | -83.0% | 0.01% | -91.3% |
| Q4 2021 | $1,771,000 | -25.9% | 13,165 | -29.0% | 0.07% | -6.8% |
| Q1 2021 | $2,390,000 | – | 18,547 | – | 0.07% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vivo Capital, LLC | 1,797,745 | $265,886,000 | 19.06% |
| RA Capital Management | 4,914,955 | $726,922,000 | 14.16% |
| Sofinnova Investments, Inc. | 1,109,874 | $164,150,000 | 10.35% |
| Eventide Asset Management | 1,709,848 | $252,887,000 | 5.50% |
| Asymmetry Capital Management, L.P. | 47,599 | $7,040,000 | 5.39% |
| BERYLSON CAPITAL PARTNERS, LLC | 58,200 | $8,608,000 | 5.30% |
| Avoro Capital Advisors LLC | 1,750,000 | $258,825,000 | 5.12% |
| Eversept Partners, LP | 220,344 | $32,588,878 | 4.47% |
| Spyglass Capital Management LLC | 452,104 | $66,866,000 | 4.14% |
| Orbimed Advisors | 1,562,986 | $231,166,000 | 3.25% |